Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen’s in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a ...

The Singularity Sapiens Mouse is engineered to produce robust immune responses across a broad range of antigens, enabling efficient discovery of fully human VH-only antibodies with strong ...

Leveragen Announces Strategic Collaboration with Moonlight Bio to Advance T Cell Therapies. The collaboration integrates Leveragen’s proprietary Singularity Sapiens Mouse platform, a groundbreaking ...

BOSTON--(BUSINESS WIRE)--Dapu Biotechnology (DPBIO), an industry leader in droplet microfluidic technology, and Leveragen, Inc., a Boston-based biotech developing advanced genetic models for antibody ...

Nanobodies, or single-domain antibodies, are only about 10% the size of traditional antibodies, yet retain high target-binding affinity, exhibit enhanced tissue penetration, and can tackle ...

Leveragen is a biotechnology company developing next-generation in vivo platforms for antibody discovery. Its proprietary platform portfolio includes the Singularity Suite for single-domain antibody ...

Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, today announced a collaboration agreement with Daiichi Sankyo (TSE: 4568) to ...

BOSTON--(BUSINESS WIRE)--#ADCs--Leveragen, Inc., a Boston-based biotechnology company advancing next-generation in vivo antibody discovery, announced today the issuance of a patent in Japan covering ...

The collaboration further supports Leveragen’s strategy of working with leading pharmaceutical and biotechnology companies to apply its in vivo discovery platforms in early-stage research and ...